Combined molecular subclass and immune phenotype correlate to atezolizumab plus radiation therapy response in invasive bladder cancer: BPT-ART Phase II study.
Nagumo Y, Hattori K, Kimura T, Sekino Y, Naiki T, Kobayashi Y, Matsumoto T, Osawa T, Kita Y, Takemura M, Mathis BJ, Suzuki S, Tsuzuki T, Ishikawa H, Nishiyama H.
Nagumo Y, et al. Among authors: kobayashi y.
Int J Radiat Oncol Biol Phys. 2025 Jan 2:S0360-3016(24)03774-X. doi: 10.1016/j.ijrobp.2024.12.019. Online ahead of print.
Int J Radiat Oncol Biol Phys. 2025.
PMID: 39755215